Ocul.O

Oculis maintains a robust liquidity position with $737.1 million in cash and equivalents against total liabilities of $153.7 million, resulting in a debt-to-equity ratio of 0.0. The company’s market capitalization stands at $1.96 billion, trading at a price-to-book ratio of 3.0. Despite strong cash reserves, the firm reports negative operating cash flow of -$204.9 million, reflecting significant investment in its pipeline. The balance sheet shows total assets of $808.1 million and total equity of $654.3 million, indicating a capital structure heavily reliant on equity financing rather than debt.

Profitability metrics are negative, consistent with a pre-commercial biopharmaceutical profile. The company reports a net loss of -$265.9 million and an operating loss of -$270.0 million on revenue of $52.0 million. Return on equity is -44.4% and return on assets is -36.0%, both significantly below typical industry medians for profitable peers, though expected for this stage of development. The enterprise value-to-revenue multiple is 23.6x, while EV/EBITDA is negative, highlighting that valuation is driven by future pipeline potential rather than current earnings.

Revenue concentration is not detailed in segment or geographic breakdowns, but the total revenue of $52.0 million suggests limited commercial scale. The absence of segment data implies that revenue is likely derived from a small number of licensing deals or milestone payments rather than broad product sales. This lack of diversification in revenue streams is typical for companies focused on advancing a narrow pipeline of drug candidates.

Growth trajectory is difficult to assess from the single-period financial snapshot provided. However, the substantial cash burn of over $200 million in operating cash flow suggests aggressive spending on research and development. The company’s ability to sustain this trajectory depends on successful clinical outcomes and potential future financing or partnership deals. Without historical period data, long-term revenue trends cannot be quantified, but the current cash position provides a runway for continued operations.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The primary risks are operational, centered on the success of clinical trials and regulatory approvals. The negative cash flow and lack of profitable operations expose the company to execution risk, where failure to meet clinical milestones could significantly impact valuation. The low dilution risk suggests that the current share count of 215.9 million is stable, with no immediate pressure from options or convertible debt.

Recent observations include strong analyst sentiment, with a mean price target of $26.73 and a median of $28.00, significantly above the current market price of $9.10. The mean recommendation is 1.67, with 4 strong buys and 8 buys, indicating high confidence in the company’s prospects. News events reflect internal data reconciliation processes rather than fundamental business changes, suggesting no recent negative catalysts. The disparity between the current price and analyst targets may reflect market skepticism about near-term clinical outcomes or broader sector sentiment.

Revenue $10.8M, +0,8% YoY; Operating income −46,0% YoY.

• ▍Revenue $10.8M, +0,8% YoY
• ▍Operating income −46,0% YoY
• ▍Net income −38,3% YoY
• ▍Free cash flow −41,5% YoY
• ▍Net margin -821.6%

Revenue $13.2M, −22,4% YoY; Operating income −37,9% YoY.

• ▍Revenue $13.2M, −22,4% YoY
• ▍Operating income −37,9% YoY
• ▍Net income −33,6% YoY
• ▍Free cash flow −39,1% YoY
• ▍Net margin -488.0%

Revenue $14.5M, −5,7% YoY; Operating income −49,4% YoY.

• ▍Revenue $14.5M, −5,7% YoY
• ▍Operating income −49,4% YoY
• ▍Net income −90,2% YoY
• ▍Free cash flow −108,7% YoY
• ▍Net margin -477.3%

Revenue $13.5M, −18,1% YoY; Operating income −55,2% YoY.

• ▍Revenue $13.5M, −18,1% YoY
• ▍Operating income −55,2% YoY
• ▍Net income −54,9% YoY
• ▍Free cash flow −56,2% YoY
• ▍Net margin -503.9%

Revenue $10.7M; Operating income -$63.9M.

• ▍Revenue $10.7M
• ▍Operating income -$63.9M
• ▍Net margin -598.7%

Revenue $17.1M; Operating income -$50.6M.

• ▍Revenue $17.1M
• ▍Operating income -$50.6M
• ▍Net margin -283.3%

Revenue $15.4M; Operating income -$46.0M.

• ▍Revenue $15.4M
• ▍Operating income -$46.0M
• ▍Net margin -236.6%

Revenue $16.4M; Operating income -$43.6M.

• ▍Revenue $16.4M
• ▍Operating income -$43.6M
• ▍Net margin -266.3%

Revenue $52.0M, −18,5% YoY; Operating income −35,2% YoY.

• ▍Revenue $52.0M, −18,5% YoY
• ▍Operating income −35,2% YoY
• ▍Net income −37,4% YoY
• ▍Free cash flow −43,2% YoY
• ▍Net margin -511.9%

Revenue $63.7M, +9,0% YoY; Operating income −192,9% YoY.

• ▍Revenue $63.7M, +9,0% YoY
• ▍Operating income −192,9% YoY
• ▍Net income −139,7% YoY
• ▍Free cash flow −127,8% YoY
• ▍Net margin -303.7%

Revenue $58.4M, +13,5% YoY; Operating income +13,3% YoY.

• ▍Revenue $58.4M, +13,5% YoY
• ▍Operating income +13,3% YoY
• ▍Net income −13,7% YoY
• ▍Free cash flow −15,4% YoY
• ▍Net margin -138.1%

Revenue $51.5M, +18,3% YoY; Operating income −0,8% YoY.

• ▍Revenue $51.5M, +18,3% YoY
• ▍Operating income −0,8% YoY
• ▍Net income −984,0% YoY
• ▍Free cash flow −1 264,0% YoY
• ▍Net margin -138.0%